{"organizations": [], "uuid": "3e9ed4c1afef457b37ab055d293ba313d8efb836", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dar-bioscience-announces-effective/brief-dar-bioscience-announces-effective-license-collaboration-deal-for-topical-sildenafil-idUSFWN1Q517Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-16T00:13:00.000+02:00", "replies_count": 0, "uuid": "3e9ed4c1afef457b37ab055d293ba313d8efb836"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dar-bioscience-announces-effective/brief-dar-bioscience-announces-effective-license-collaboration-deal-for-topical-sildenafil-idUSFWN1Q517Q", "ord_in_thread": 0, "title": "BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil", "locations": [], "entities": {"persons": [{"name": "coll", "sentiment": "neutral"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters) - dare bioscience inc", "sentiment": "neutral"}, {"name": "bioscience", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER\n* DARE BIOSCIENCE SAYS MET FUNDING REQUIREMENT FOR OBTAINING EXCLUSIVE WORLDWIDE LICENSE TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM)\n* DARE BIOSCIENCE - PLANS TO PURSUE 505(B)(2) REGULATORY PATHWAY FOR SST-6007 IN U.S.\n* DARE BIOSCIENCE - FUNDS WILL BE USED TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM) THROUGH NEXT PHASE OF CLINICAL DEVELOPMENT\n* DARE BIOSCIENCE INC - ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL FOR SST-6007 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-16T00:13:00.000+02:00", "crawled": "2018-02-16T17:15:26.010+02:00", "highlightTitle": ""}